Division of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Division of Trauma and Acute Care Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Ann Surg Oncol. 2022 Oct;29(11):6593-6602. doi: 10.1245/s10434-022-11949-8. Epub 2022 May 31.
Appendiceal cancer with peritoneal metastases (ACPM) is a complex disease requiring multidisciplinary care. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion (CRS HIPEC) can significantly improve survival but requires evaluation by a surgical oncologist and significant treatment endurance. The impacts of socioeconomic status (SES) and other social determinants of health on rates of surgical evaluation and treatment have not been examined.
We conducted a retrospective cohort study examining all patients with ACPM from 2010 to 2018 in a regional healthcare system. Patient characteristics, oncologic details, treatment strategies, and survival were examined. The primary outcomes of interest were referral to Surgical Oncology, receipt of CRS HIPEC, and survival.
Of 194 patients identified, 94% had synchronous ACPM. The majority of patients (95%) were referred to surgical oncology. Advanced age was the only predictor of nonreferral (p < 0.001). A total of 147 patients (76%) ultimately underwent CRS HIPEC. After adjusting for medical and tumor characteristics, CRS HIPEC was less likely for patients who were unmarried [odds ratio (OR) 0.253, p = 0.004] or of low SES (OR 0.372, p = 0.03). On subanalysis of patients undergoing CRS HIPEC, median overall survival was worse for patients of low SES [51 months versus not reached (NR), p = 0.05], and this disparity persisted on multivariate analysis [hazard ratio (HR) = 2.278, p = 0.001].
This analysis is the first to evaluate barriers to CRS HIPEC for ACPM. While most patients were evaluated by a multidisciplinary team, nonmedical factors may play a role in the treatment received and ultimate outcomes. Addressing these disparities is crucial for ensuring equitable outcomes and improving patient care.
阑尾癌伴腹膜转移(ACPM)是一种需要多学科治疗的复杂疾病。细胞减灭术和腹腔热灌注化疗(CRS HIPEC)可以显著提高生存率,但需要外科肿瘤学家进行评估,并需要患者有较强的治疗耐受力。社会经济地位(SES)和其他健康社会决定因素对手术评估和治疗率的影响尚未得到研究。
我们进行了一项回顾性队列研究,对 2010 年至 2018 年在一个区域医疗系统中所有患有 ACPM 的患者进行了研究。检查了患者的特征、肿瘤学细节、治疗策略和生存情况。主要关注的结果是转诊至外科肿瘤学、接受 CRS HIPEC 治疗和生存情况。
在确定的 194 名患者中,94%的患者为同步性 ACPM。大多数患者(95%)被转诊至外科肿瘤学。高龄是未转诊的唯一预测因素(p < 0.001)。共有 147 名患者(76%)最终接受了 CRS HIPEC。在调整了医疗和肿瘤特征后,未婚患者(OR 0.253,p = 0.004)或 SES 较低的患者接受 CRS HIPEC 的可能性较低。在接受 CRS HIPEC 治疗的患者亚分析中,SES 较低的患者的中位总生存期较差[51 个月与未达到(NR),p = 0.05],并且在多变量分析中这种差异仍然存在[风险比(HR)= 2.278,p = 0.001]。
这项分析是第一个评估 ACPM 患者接受 CRS HIPEC 治疗的障碍的研究。虽然大多数患者都由多学科团队进行了评估,但非医疗因素可能会对接受的治疗和最终结果产生影响。解决这些差异对于确保公平的结果和改善患者护理至关重要。